1. Home
  2. HG vs NKTR Comparison

HG vs NKTR Comparison

Compare HG & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Insurance Group Ltd. Class B

HG

Hamilton Insurance Group Ltd. Class B

HOLD

Current Price

$34.74

Market Cap

2.4B

Sector

N/A

ML Signal

HOLD

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

HOLD

Current Price

$69.12

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HG
NKTR
Founded
2013
1990
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.2B
IPO Year
2023
1996

Fundamental Metrics

Financial Performance
Metric
HG
NKTR
Price
$34.74
$69.12
Analyst Decision
Buy
Strong Buy
Analyst Count
8
7
Target Price
$32.00
$146.67
AVG Volume (30 Days)
291.5K
509.5K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
6.26%
N/A
EPS Growth
51.23
N/A
EPS
2.73
N/A
Revenue
$2,905,524,000.00
$307,711,000.00
Revenue This Year
$1.80
N/A
Revenue Next Year
$12.52
N/A
P/E Ratio
$12.59
N/A
Revenue Growth
24.70
86.00
52 Week Low
$22.66
$33.40
52 Week High
$37.31
$109.00

Technical Indicators

Market Signals
Indicator
HG
NKTR
Relative Strength Index (RSI) 44.95 44.65
Support Level $33.49 $70.24
Resistance Level $36.11 $76.49
Average True Range (ATR) 0.68 2.88
MACD -0.10 -0.31
Stochastic Oscillator 15.38 15.34

Price Performance

Historical Comparison
HG
NKTR

About HG Hamilton Insurance Group Ltd. Class B

Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select, and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Share on Social Networks: